UT Health San Antonio Multispecialty and Research Hospital says it’s the first in Texas to add a new non-opioid medication to ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

Nicolette Natale, D.O., whose areas of expertise include the treatment of substance abuse disorders. Courtesy Nicolette Natale, D.O. According to ...

“The phase 3 safety and efficacy across the three studies are impressive and demonstrate VX-548’s potential to change the paradigm of pain management ... painkiller Journavx, and a partnership ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of moderate-to-severe acute pain following ... painkiller Journavx, and a ...

In today’s spine and pain management landscape, the only thing more overwhelming than the condition itself is the sheer ...

Researchers developed a novel ultrasonic implant that shows promise for personalized, efficient, and minimally invasive ...

The FDA has approved Xifyrm for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.